TY  - JOUR
AU  - Valente, Andreia
AU  - Podolski-Renić, Ana
AU  - Poetsch, Isabella
AU  - Filipović, Nenad
AU  - López, Óscar
AU  - Turel, Iztok
AU  - Heffeter, Petra
PY  - 2021
UR  - https://linkinghub.elsevier.com/retrieve/pii/S1368764621000364
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/4463
AB  - Drug resistance remains the major cause of cancer treatment failure especially at the late stage of the disease. However, based on their versatile chemistry, metal and metalloid compounds offer the possibility to design fine-tuned drugs to circumvent and even specifically target drug-resistant cancer cells. Based on the paramount importance of platinum drugs in the clinics, two main areas of drug resistance reversal strategies exist: overcoming resistance to platinum drugs as well as multidrug resistance based on ABC efflux pumps. The current review provides an overview of both aspects of drug design and discusses the open questions in the field. The areas of drug resistance covered in this article involve: 1) Altered expression of proteins involved in metal uptake, efflux or intracellular distribution, 2) Enhanced drug efflux via ABC transporters, 3) Altered metabolism in drug-resistant cancer cells, 4) Altered thiol or redox homeostasis, 5) Altered DNA damage recognition and enhanced DNA damage repair, 6) Impaired induction of apoptosis and 7) Altered interaction with the immune system. This review represents the first collection of metal (including platinum, ruthenium, iridium, gold, and copper) and metalloid drugs (e.g. arsenic and selenium) which demonstrated drug resistance reversal activity. A special focus is on compounds characterized by collateral sensitivity of ABC transporter-overexpressing cancer cells. Through this approach, we wish to draw the attention to open research questions in the field. Future investigations are warranted to obtain more insights into the mechanisms of action of the most potent compounds which target specific modalities of drug resistance.
PB  - Edinburgh: Churchill Livingstone
T2  - Drug Resistance Updates
T1  - Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance.
VL  - 58
DO  - 10.1016/j.drup.2021.100778
SP  - 100778
ER  - 

@article{
author = "Valente, Andreia and Podolski-Renić, Ana and Poetsch, Isabella and Filipović, Nenad and López, Óscar and Turel, Iztok and Heffeter, Petra",
year = "2021",
abstract = "Drug resistance remains the major cause of cancer treatment failure especially at the late stage of the disease. However, based on their versatile chemistry, metal and metalloid compounds offer the possibility to design fine-tuned drugs to circumvent and even specifically target drug-resistant cancer cells. Based on the paramount importance of platinum drugs in the clinics, two main areas of drug resistance reversal strategies exist: overcoming resistance to platinum drugs as well as multidrug resistance based on ABC efflux pumps. The current review provides an overview of both aspects of drug design and discusses the open questions in the field. The areas of drug resistance covered in this article involve: 1) Altered expression of proteins involved in metal uptake, efflux or intracellular distribution, 2) Enhanced drug efflux via ABC transporters, 3) Altered metabolism in drug-resistant cancer cells, 4) Altered thiol or redox homeostasis, 5) Altered DNA damage recognition and enhanced DNA damage repair, 6) Impaired induction of apoptosis and 7) Altered interaction with the immune system. This review represents the first collection of metal (including platinum, ruthenium, iridium, gold, and copper) and metalloid drugs (e.g. arsenic and selenium) which demonstrated drug resistance reversal activity. A special focus is on compounds characterized by collateral sensitivity of ABC transporter-overexpressing cancer cells. Through this approach, we wish to draw the attention to open research questions in the field. Future investigations are warranted to obtain more insights into the mechanisms of action of the most potent compounds which target specific modalities of drug resistance.",
publisher = "Edinburgh: Churchill Livingstone",
journal = "Drug Resistance Updates",
title = "Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance.",
volume = "58",
doi = "10.1016/j.drup.2021.100778",
pages = "100778"
}

Valente, A., Podolski-Renić, A., Poetsch, I., Filipović, N., López, Ó., Turel, I.,& Heffeter, P.. (2021). Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance.. in Drug Resistance Updates
Edinburgh: Churchill Livingstone., 58, 100778.
https://doi.org/10.1016/j.drup.2021.100778

Valente A, Podolski-Renić A, Poetsch I, Filipović N, López Ó, Turel I, Heffeter P. Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance.. in Drug Resistance Updates. 2021;58:100778.
doi:10.1016/j.drup.2021.100778 .

Valente, Andreia, Podolski-Renić, Ana, Poetsch, Isabella, Filipović, Nenad, López, Óscar, Turel, Iztok, Heffeter, Petra, "Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance." in Drug Resistance Updates, 58 (2021):100778,
https://doi.org/10.1016/j.drup.2021.100778 . .